Digital symptom checkers (SCs) are increasingly used to support early symptom recognition and care-seeking, yet evidence on their cost-effectiveness remains limited. We conducted an economic evaluation of a digital SC …
Nearly a century has passed since a seminal review article was published in 1928 in Archives of Pathology on ectopic endometriosis, presenting the dominant pathogenetic theories of the era: the …
The development of prostaglandins and antiprogestins revolutionized medical abortion by providing effective nonsurgical options for terminating pregnancy. Although both strategies are accepted in practice, variations in clinical efficacy, patient experiences, …
The objective was to evaluate the clinical and demographic characteristics of patients undergoing endometriosis surgery in the public healthcare system, estimate the direct costs related to low- and high-complexity procedures, …
Endometriosis affects 1 in 10 Canadians, yet its financial toxicity remains poorly understood. While universal healthcare covers physician and hospital services, patients face substantial out-of-pocket costs for medications, complementary therapies, …
Chronic pelvic pain, defined as persistent pain in the structures of the pelvis, is a condition that significantly impacts the health-related quality of life (HRQoL) of up to one-third of …
Endometriosis affects 1 in 10 women globally. We aimed to determine health provider involvement and preferred methods of obtaining an endometriosis diagnosis across international jurisdictions. A global cross-sectional survey, distributed …
Endometriosis is a significant and prevalent health issue. Delayed diagnosis is common and the associated delay to treatment is associated with high socioeconomic and personal costs including chronic pain, infertility …
To compare the efficacy of ultrasound-guided alcohol sclerotherapy versus laparoscopic cystectomy for the management of ovarian endometriomas, focusing on complications, recurrence, pain relief, and healthcare costs.
To demonstrate, using actual insurance data, that benign pelvic conditions are associated with increased healthcare costs and that these costs increase further with each additional coexisting benign pelvic diagnoses.